Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
09 September 2016 - 11:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-35144
Sagent
Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
1901 N. Roselle Road,
Suite 700,
Schaumburg,
Illinois 60195
Telephone (847) 908-1600
(Address, including zip code, and telephone number, including area code, of registrants principal executive officers)
Common Stock, $ 0.01 par value per Share
(Title of each class of securities covered by this Form)
None
(Title of all other
classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the
box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
|
|
|
Rule 12g-4(a)(1)
|
|
x
|
Rule 12g-4(a)(2)
|
|
¨
|
Rule 12h-3(b)(1)(i)
|
|
x
|
Rule 12h-3(b)(1)(ii)
|
|
¨
|
Rule 15d-6
|
|
¨
|
Approximate number of holders of record as of the certification or notice date: One.
Pursuant to the requirements of the Securities Exchange Act of 1934, Sagent Pharmaceuticals, Inc. has caused this certification/notice to be signed on its
behalf by the undersigned duly authorized person.
|
|
|
|
|
Date: September 9, 2016
|
|
By:
|
|
/s/ Allan Oberman
|
|
|
Name:
|
|
Allan Oberman
|
|
|
Title:
|
|
Chief Executive Officer
|
Sagent (NASDAQ:SGNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sagent (NASDAQ:SGNT)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Sagent Pharmaceuticals, Inc. (NASDAQ): 0 recent articles
More Sagent Pharmaceuticals, Inc. News Articles